2018 American Society of Hematology Annual Meeting*

Hematology 2018 Conference Image
Download All
December 1-4, 2018; San Diego, California
Review slidesets and analyses of key data from the 2018 Hematology meeting.

Other Hematologic Diseases

Capsule Summary Slidesets

Luspatercept significantly reduced transfusion burden and improved hemoglobin levels compared with placebo for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndrome with ring sideroblasts.

Released: December 17, 2018

Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.

Released: December 4, 2018

Randomized study observed EFS benefit associated with deferasirox-based iron chelation therapy in lower-risk MDS.

Released: December 5, 2018

Combination therapy achieved objective clinical improvements in disease status, including durable hematologic responses.

Released: December 11, 2018

Immune checkpoint inhibitors ipilimumab and nivolumab were active in MDS, both individually in the setting of HMA failure and combined with 5-azacitidine in the frontline setting, producing promising survival and response outcomes with acceptable toxicity profiles.

Released: December 12, 2018

Rapid and durable responses to the selective JAK1/JAK2 inhibitor ruxolitinib plus corticosteroids were observed across all patient subgroups defined by baseline steroid-refractory criteria, organ involvement, and disease stage.

Released: December 12, 2018

In an intraindividual comparison, emicizumab prophylaxis was associated with a greatly reduced risk of treated bleeds compared with prior treatment with bypassing agents.

Released: December 7, 2018

In MF patients with poor prognosis following failure of JAK inhibition, a high dose of imetelstat, an investigational telomerase inhibitor, was associated with markedly longer median OS compared with historical data.

Released: December 6, 2018

In this early study, the addition of pulsed dexamethasone to eltrombopag as frontline therapy for ITP appeared safe and effective with prolonged responses.

Released: December 5, 2018

Early initiation of defibrotide in adults with post-HSCT VOD/SOS improves Day +100 survival regardless of renal/pulmonary dysfunction status.

Released: December 14, 2018

In this analysis of gastric biomarkers from 2 phase III trials, no significant gastric toxicity was associated with the use of avatrombopag to treat thrombocytopenia in patients with chronic ITP.

Released: December 6, 2018

In ambulatory patients with cancer, rivaroxaban significantly reduced VTE with a low incidence of major bleeding, and with the use of the Khorana score cutoff of 2 or higher identifying patients at high risk of thrombotic events.

Released: December 11, 2018
Provided by the Annenberg Center for Health Sciences at Eisenhower.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Gilead Sciences
Jazz Pharmaceuticals, Inc.
Novartis Pharmaceuticals Corporation
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings